San Diego-based mostly Viking Therapeutics marked by itself as a significant competitor in the weight loss drug sector in February soon after revealing promising details from the mid-phase trial of experimental drug VK2735, which recommended it rivaled—and outperformed—Novo and Lilly drugs when specified as being a weekly injection As well as i